Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
Argenx to Present at Upcoming Investor Conferences
Evercore ISI Raises Price Target on Argenx to $555 From $533, Keeps Outperform Rating
What 25 Analyst Ratings Have To Say About Argenx
Argenx Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $640
European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading
Biotech Stocks: Which Drugmakers Are Worth a Buy?
10 Health Care Stocks With Whale Alerts In Today's Session
Piper Lists Eight Defensive Biotechs to Face Market Volatility
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Express News | Barclays Upgrades Argenx to Overweight
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), IGC Pharma (IGC) and Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
Express News | Argenx SE : Baird Raises Target Price to $515 From $490
The Analyst Verdict: Argenx In The Eyes Of 27 Experts
Jefferies Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $598
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Baird Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $515
Truist Financial Maintains Argenx SE(ARGX.US) With Buy Rating